Structured Immunity logo

Structured Immunity

Structured Immunity is a protein engineering company making T cell based therapies safer by enhancing the target specificity of T cell receptors Structured Immunity is a protein engineering company specializing in the optimization and validation of T cell receptor (TCR) proteins to improve the safety of T cell based therapies.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://structuredimmunity.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1400 East Angela Blvd, IN
South Bend
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/structured-immunity” connections=”true” suffix=””]

Structured Immunity proprietary protein engineering platform enables immuno-oncology development and integrates structural biology, immunology, and protein biophysics for predictively validating and optimizing lead TCR candidates for immunotherapy.

In Aug 2018, Structured Immunity signed research collaboration with Medigene AG, to provide structural immunology expertise in support of Medigenes TCR discovery activities. Under the terms, Medigene will supply Structured Immunity with a lead TCR candidate for a high-profile solid tumor target. Structured Immunity will evaluate the TCRs specificity and recognition properties using their established structural immunology technologies.

In May 2017, Structured Immunity received a Grant worth $15k from an undisclosed investor.